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Fatty Acids and Lipotoxic Disease
The obesity epidemic is fueled by intake of calorie dense foods in excess of that needed for growth and development and to maintain health. Among the nutritional components correlated with increased disease risk are fats, particularly saturated and trans-unsaturated fatty acids. Few drugs are currently available to treat obesity, which is now classified as a disease affecting 34.9 percent of adults and 16.9 percent of children and adolescents 1 . Of these, most drugs generally seek to suppress appetite or decrease fat digestion to limit absorption in the intestine [2] [3] [4] [5] [6] . A member of the first class is phenteramine, which is also accompanied by adverse cardiovascular events [7] [8] [9] . Orlistat is a member of the second class of drugs 10, 11 . This drug acts to inhibit pancreatic lipase and is associated with gastrointestinal disturbances. In addition, the use of orlistat for one year only results in modest weight reduction. Given the health imperative and economic burden of the obesity epidemic and the lack of treatment options, alternative methods must be found to decrease the prevalence of obesity, limit the toxic effects of fatty acids, or interrupt the molecular mechanisms that link excessive accumulation in fatty acids to debilitating diseases.
Chronic imbalances in lipid flux and metabolism often cause a variety of metabolic abnormalities and pathologies, including hyperlipidemia, type two diabetes (T2D), nonalcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and some cancers [12] [13] [14] . A name given to the cellular dysfunction caused by high levels of intracellular fatty acids is lipotoxicity [15] [16] [17] [18] [19] [20] [21] . For most tissues, the excess fatty acids are derived from an extracellular source (i.e., diet) when blood levels of triglycerides and free fatty acids are chronically elevated. However, de novo synthesis in liver of fatty acids and triglycerides can also add to the burden of systemic lipid overload when dietary carbohydrate is consumed chronically at levels above the amount required to meet daily energy demands. Apart from adipocytes, most cells have a limited capacity for lipid storage and when this capacity is exceeded, cell death may result from lipotoxicity characterized by ER stress, mitochondrial and nuclear dysfunction 19, 22, 23 . Obesity is a common initiating condition for these diseases due to chronic hyperlipidemia and elevated free fatty acids. Current evidence indicates free fatty acids and/or their metabolites mediate cell death, although the exact mechanism is poorly understood 22, [24] [25] [26] . Lipid overload in muscle can
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lead to insulin resistance and in pancreatic β-cells may lead to dysregulation of insulin secretion and apoptotic cell death, both of which may contribute to the genesis of the diabetic state [27] [28] [29] .
Lipoapoptosis is also observed in the heart, which leads to the development of heart failure [30] [31] [32] .
In liver, chronically elevated fat deposits result in NAFLD, which can lead to steatohepatitis (NASH) and, eventually, to non-reversible hepatic cirrhosis 25, 33 . Therefore, there is much interest in preventing abnormal lipid accumulation, which can lead to lipotoxicity, metabolic dysfunction, and disease. Given the role of free fatty acids in lipotoxicity, one target to prevent or resolve lipotoxic disease is fatty acid uptake into cells.
The development of drugs to prevent lipotoxic disease requires the determination components and mechanisms that contribute to and regulate normal lipid homeostasis, particularly with regard to fatty acid metabolism. Our mechanistic work has focused on the role of the Slc27a family of proteins also known as Fatty Acid Transport Proteins (FATP) [34] [35] [36] [37] [38] [39] [40] . To date six family members have been identified in humans, FATP1-6 (i.e., Slc27a1 through Slc27a6) 41 . Among these, we have focused our efforts on FATP2 because of its role in fatty acid transport and trafficking, especially in liver and intestine where it is highly expressed.
Expression of FATP2 in liver is consistent with a primary role in fatty acid transport and metabolism; when its expression is increased there is a correlative increase in the progression of NAFLD 42 . Recently, FATP2 was identified as a molecular marker for obesity in peripheral blood mononuclear cells 43 and was elevated in livers of adolescents with NASH 44 . Decreased expression of FATP2 in liver using shRNA reduces fatty acid transport and protects mice from diet-induced NAFLD 45 . There is evidence the winged helix/forkhead box (Fox) transcription factor Foxa1 is required for repression of FATP2; the expression of Foxa1 results in decreased FATP2 levels and reduced fatty acid uptake in hepatocytes 46 . In this regard Foxa1 expression may function, in part, to protect liver from steatosis through the regulation of FATP2. In primary rat hepatocytes the development of lipotoxicity by palmitate is correlated with increased 48 . Given that exogenous fatty acids directly contribute to NAFLD 49, 50 , these finding are of particular importance to inform work directed at preventing lipotoxicity in susceptible tissues.
Fatty Acid Transport Through Vectorial acylation
Like glucose transport that is coupled to phosphorylation, one mechanism that drives fatty acid transport into cells is coupled to esterification with coenzyme A (vectorial acylation) 35 . This hypothesis of vectorial acylation, concomitant fatty acid transport and activation was put forth by Overath and co-workers in 1969 and arose from their studies in E. coli 51 . This seminal work demonstrated that a long chain acyl CoA synthetase (Acsl) is required to target the fatty acids for metabolism in E coli. Importantly, these studies demonstrated that free fatty acids did not accumulate in cells where fatty acids were provided as the sole carbon and energy source, but rather acyl CoA derivatives were detected. E coli cells lacking the structural gene encoding the Acsl, fadD, are unable to transport exogenous fatty acids further supporting this concept.
Mechanistically, it is thought the bacterial Acsl partitions into the inner membrane in response to exogenous long chain fatty acids where this enzyme abstracts the fatty acid substrate concomitant with catalysis to produce fatty acyl CoA [52] [53] [54] [55] . The resultant acyl-CoA is the ligand of the transcription factor FadR. The FadR-acyl-CoA complex cannot bind DNA, thus inducing the expression of genes encoding fatty acid degrading enzymes and the fatty acid transporter FadL, while also reducing the expression of genes encoding tow genes required for unsaturated fatty acid biosynthesis. This foundational work in bacteria describing the process of vectorial acylation, the generation of long chain acyl CoA and transcriptional regulatory network has established the basis for addressing this process in eukaryotic systems 54 .
In the yeast Saccharomyces cerevisiae, the process of vectorial acylation is operational, but with increased complexity. The yeast Fat1 protein (Fat1p; YBR041W) was identified by structural and functional similarities to members of the FATP family 56 . Deletion of the yeast FAT1 gene, encoding Fat1p, disrupts fatty acid transport measured using both radioactive substrates and the fluorescent fatty acid analogue, C 1 -BODIPY-C 12 56 . The reduction in fatty acid transport in fat1∆ strains is also associated with inability of yeast cells to grow under conditions where cells are auxotrophic for long chain fatty acids such as during hypoxia when the fatty acyl CoA ∆9 desaturase (Ole1p) is inactive. Fat1p-dependent fatty acid uptake is specific for long chain fatty acids (C16-C20).
Like several mammalian FATPs, Fat1p is a dual functional protein with acyl CoA synthetase activity specific for very long chain fatty acids (>C20; Vlacs). Deletion of FAT1 reduces activation of lignoceric acid (C 24:0 ) and results in the accumulation of very long chain fatty acids 52, 57, 58 . Importantly, alanine scanning mutagenesis of the yeast FAT1 generated altered forms of Fat1p that have activities that separate fatty acid transport from fatty acid activation 59 . Three additional lines of evidence further support the conclusion the transport and activation activities in different members of the FATP protein family distinct. First, the expression of FATP1, 2 and 4 in yeast results in increased Vlacs (i.e., C 24:0 or C 20:4 ) activity but has no affect on Acsl activity using long chain fatty acid substrates (i.e., C 14:0 or C 18:1 ) 60 . FATP 5 and 6 do not function in this capacity, nor do they complement transport deficiencies in yeast fat1∆ strains. Second, the characterization of five different murine FATP1, 4, and 6 protein chimeras distinguished fatty acid transport and activation 36 . And third, two splice variants of human FATP2 (2a and 2b) are expressed in various tissues 35, 37, 59, 61 . Variant 2b is missing exon 3 encoding the ATP/AMP binding site and functions in fatty acid transport but not fatty acid 
FATP/Scl27 Family Members as Drug Targets
As summarized above, the fatty acid transport proteins (FATP) are classified as members of the Solute Carrier 27 (Slc27) family of proteins 35, 41, 63, 64 and have been evaluated
for their ability to promote the transport of exogenous fatty acids in a number of different cell types 34-36, 41, 47, 56, 59, 60, 62-80 . The first fatty acid transport protein, FATP1, as well as Acsl1 was identified using expression cloning from a cDNA library prepared from murine 3T3-L1 adipocytes directly demonstrating its physiological role in the net accumulation of fatty acids 80 .
A number of different isoforms of FATP have subsequently been identified experimentally in mice, rats, humans, C. elegans, Drosophila and yeast 56, 58, 62, 63, 67, 68, 78, [80] [81] [82] . In mammals there are six isoforms that differ based on their tissue and cell type distribution, regulation and preferred substrate 73 . While the expression of each of these proteins has been correlated with increased levels of fatty acid transport, several have also been described as very long chain acyl CoA synthetases (Vlacs). Indeed prior to the classification of this family of proteins as members of the Slc27 family, several were first described as very long chain acyl CoA synthetases, and based on their sequence encoding an ATP binding domain clearly fall into the larger family of adenylate-forming enzymes 45, 71, [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] . One member of this family, FATP4, plays a major role in vivo in maintaining the barrier function of the skin through ceramide metabolism and contributes to the epidermal barrier function 64, 70 . Another, FATP5, has activation activity towards bile acids and is involved in secondary bile acid metabolism 92, 93 . Finally, there is evidence these proteins are localized to the endoplasmic reticulum in addition to the plasma membrane, which may occur at regions of juxtaposition between the two membranes (e.g., see 94, 95 ). None-the-less, both knockdown and over expression studies of several members of the FATP family are consistent with the conclusion they function in the process governing the transport exogenous fatty acids into the cell in a highly regulated manner.
Given their important roles in fatty acid transport, the FATP proteins are viewed as viable targets to prevent aberrant accumulation of fat in cells and tissues that leads to lipotoxic disease. FATP1 and FATP4 have been used to select inhibitors by high through put screening 96, 97 . In each screen, acyl CoA synthetase activity was targeted and not fatty acid transport directly. It was rationalized that the Acsl activity was essential for transport activity due to coupled activation and transport. However, from our work in yeast, the activation and transport activities are separable 36, 59, 61 . FATP1 was particularly chosen as a therapeutic target for the treatment of insulin resistance and various arylpiperazines were selected as inhibitors 96 .
However, upon testing in mice, the selected compound imidazolepyridine, did not limit the accumulation of triglyceride in muscle when mice were fed a high fat diet leading to the conclusion that inhibition of FATP1 alone is insufficient to block fatty acid transport 96 . FATP4
was originally described as the major FATP in the intestine and the rationale for its selection as a therapeutic target was to block the absorption of dietary fatty acids 97 . In this case screening studies identified dihydropyrimidinones as FATP4-specific inhibitors. Again, in subsequent in vivo studies these compounds were ineffective as inhibitors of fatty acid absorption. These results informed our choice to focus on FATP2 and to limit our screening design to fatty acid transport rather than Acsl activity.
Fatty Acid Transport Protein 2 (FATP2)
Recent work in our laboratories has focused on FATP2 (Slc27a2), which is expressed in specific tissue types, particularly the small intestine, pancreas and liver 38 . FATP2 was originally defined as a very long chain acyl CoA synthetase (Acsvl1) with an indirect role in the pathophysiology of X-linked adrenoleukodystrophy (X-ALD) 86, 87, 98 . The FATP2/Acsvl1 knockout mouse (fatp2-/-) has reduced very long chain acyl CoA synthetase (VLACS) and peroxisomal very long chain FA oxidation activities in liver, but does not accumulate very long chain fatty acids in blood, a hallmark of X-ALD. The role of FATP2 in fatty acid transport was subsequently demonstrated in both yeast and mammalian cells 37, 38, 45, 60 . Of particular importance was the identification of a splice variant of FATP2 (FATP2b) that lacks acyl CoA synthetase activity yet is fully functional in fatty acid transport demonstrating the transport activity is distinct from fatty acid activation 38 .
FATP2 is highly expressed in small intestine, liver, kidney, pancreas and placenta and to a lesser extent in brain, heart, and colon; expression is not detectable in white adipose tissue 38 (see http://www.proteinatlas.org/). FATP2 expression in the small intestinal mucosa has been confirmed and moreover shown to significantly increase in mice fed a high fat diet 99, 100 . FATP2
is the predominant FATP isoform expressed in Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line 40 . Expression of FATP2 in liver is also consistent with a key role in fatty acid transport and metabolism. In primary rat hepatocytes, the development of lipotoxicity by palmitate (C 16:0 ) is correlated with increased FATP2 expression, plasma membrane localization, and the development of insulin resistance 47 . Increased expression is linked with the progression of nonalcoholic fatty liver disease (NAFLD) 42 while decreased expression using adenoviral-directed fatp2 shRNA reduces fatty acid transport and protects mice from dietinduced NAFLD 45 . FATP2 levels increase in isolated human pancreatic islets under high glucose conditions supporting a mechanistic basis of this protein in fatty acid transport in ß cells 101 . FATP2 is the predominant isoform in INS-1E cells, a rat pancreatic β cell line 102 .
The regulation of FATP2 expression is complex. In the small intestine, FATP2 expression levels are increased four-to five-fold in response to the PPARα agonists Wy12643 and GW7647 103 . In PPARα null mice, the expression of FATP2 is decreased two-fold; the expression of FATP2 remains unchanged in PPARα null mice treated with both agonists 103 .
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There is evidence the winged helix/forkhead box (Fox) transcription factor Foxa1 regulates the expression of FATP2 in liver. As noted above, the increased expression of Foxa1 in HepG2 cells and primary human hepatocytes decreases FATP2 expression, which is correlated with approximately two-fold lower levels of fatty acid transport 46 . In this regard Foxa1 expression appears to function, in part, to protect liver from steatosis through the regulation of FATP2. The increased expression of FATP2 in liver is also associated with activation of insulin the insulin receptor substrates IRS-1 and IRS-2, which is coincident with increased lipogenesis. Given that exogenous fatty acids directly contribute to NAFLD, we suggest FATP2 is a key determinant in the development of a chronic fatty liver 49, 50, 104, 105 . Finally, and of specific interest in the context of obesity, FATP2 expression in peripheral blood mononuclear cells of rats fed a hyperlipidemic cafeteria diet was 33-fold higher than rats fed a lower fat normal caloric diet, suggesting this protein may be an ideal marker for overweight development and lipotoxicity 43 . With this information as a backdrop, the challenge at present is to target FATP2 to prevent and resolve lipotoxicity using novel small compound inhibitors to prevent associated pathologies.
Collectively, FATP2 is an attractive target to develop inhibitors that block fatty acid transport for several reasons. First, expression of FATP2 is specific to a limited number of tissues, but is highly expressed in intestine and liver 41 . Thus, inhibition is predicted to affect absorption, distribution, and over-accumulation of fatty acids in liver. Second, studies in animals and cells, as well as in human clinical studies, indicate depression of FATP2 levels in the liver is associated with decreased fatty acid uptake and is protective for NAFLD. FATP2 has been suggested as a biomarker for the development of overweight and obesity 43, 44, 46 . .
Development of High Throughput Screens to Identify Compounds that Block FATP2
To address this challenge and further understand the role of the FATP2 in fatty acid transport, activation and intracellular trafficking, we devised a screening method for small compound inhibitors that relied on the transport of the fluorescent long chain fatty acid C 1 -BODIPY-C 12 107, 108 . The primary screening method employed a yeast strain deficient in fatty acid transport (fat1∆) and with reduced Acsl activity (faa1∆). In this strain we expressed human FATP2b, which functions in fatty acid transport but is deficient in acyl CoA synthetase activity 107, 108 . The selected transport inhibitors are useful as . These data are consistent with studies using FATP2 overexpressing and knockdown cell lines treated with isotopically labeled exogenous fatty acids, which demonstrated this protein contributes to fatty acid transport through vectorial acylation 37, 38 .
The saturated fatty acid, palmitate, is a major component of the western diet and high levels of dietary intake correlate with a number of life style diseases including Type 2 diabetes and NAFLD 30, 109, 110 . Palmitic acid induces apoptosis in pancreatic β-cell lines as well as in hepatocytes 111, 112 . Lipofermata treatment blocks both palmitate-induced accumulation of lipid droplets and apoptotic cell death in a dose-dependent manner 102 . Chronic exposure of both liver and β cells to high levels of saturated fatty acids has been shown to induce apoptosis and disrupt cellular function thereby contributing to the pathogenesis of fatty liver disease (modeled in Figure 3 . On the basis of these findings, we propose Lipofermata is likely to be useful to attenuate cellular and organ lipotoxicity, which leads to disease and may be of therapeutic use in protecting β cells against lipotoxicity caused by diets high in saturated fat.
One of the predicted uses of Lipofermata is as an inhibitor of intestinal fatty acid absorption for use in mechanistic studies in animals and, perhaps eventually, as a therapeutic.
Lipofermata attenuates fatty acid absorption across the gut by 80% in a temporal manner 102 .
There are no other compounds that inhibit fatty acid absorption specifically targeting fatty acid transport. Xenical (orlistat) is an approved drug for use in inhibiting fat absorption 11 that function by inhibiting pancreatic lipase and thus triglyceride breakdown 115 . In this case, since the fatty acids are not released from the complex lipid, they cannot be absorbed. It is worth speculating that Lipofermata may be used as a partner with Xenical, which will further inhibit free fatty acid transport across the intestinal epithelium. As reviewed above, selected FATP1
and FATP4 inhibitors do not prevent fatty acid absorption 96, 97 .
Grassofermata
A second FATP2-inhibitor identified in our high throughput screen is Grassofermata, 2- 
